HIGHLIGHTS
- who: Lin Tang from the Technion Institute of, Stanford, United States have published the research work: The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients, in the Journal: (JOURNAL)
- what: All patients enrolled in this study had received HD for more than 3 months. This study showed that cTnI decreased significant in both groups, but no difference in the level of cTnI was observed between the two groups .
- how: The authors conducted the first study to explore the role of Sac/Val in HD patients with PH. The authors . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.